Diaceutics (LON:DXRX) Insider Jordan Clark Buys 100 Shares

Diaceutics PLC (LON:DXRX) insider Jordan Clark acquired 100 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was purchased at an average cost of GBX 150 per share, with a total value of £150.

Jordan Clark also recently made the following trade(s):

• On Tuesday, December 23rd, Jordan Clark bought 117 shares of Diaceutics stock. The stock was purchased at an average cost of GBX 128 per share, for a total transaction of £149.76.

Diaceutics Stock Up 2.1%

DXRX stock opened at GBX 145.50 on Friday. The company has a market cap of £123.13 million, a price-to-earnings ratio of -80.83 and a beta of 0.58. The company has a debt-to-equity ratio of 3.05, a quick ratio of 9.92 and a current ratio of 3.96. The business’s 50-day moving average is GBX 153.42 and its two-hundred day moving average is GBX 151.80. Diaceutics PLC has a fifty-two week low of GBX 106 and a fifty-two week high of GBX 176.25.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group boosted their target price on shares of Diaceutics from GBX 180 to GBX 215 and gave the company a “buy” rating in a research report on Thursday, January 15th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of GBX 193.33.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.